On November 3, Ultragenyx reported third-quarter 2026 revenue of $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI; its losses exceeded analyst expectations, and its stock fell in after-hours trading. The FDA approved the BLAs for GENGLYCOS and FAYUVI during the quarter, and the company agreed to sell two Priority Review Vouchers for a combined $413 million. On November 3 and 4, Ultragenyx announced a target of cutting 2027 R&D expenses by at least 50% versus 2025, reducing its workforce by 20%, and trimming pipeline programs. It reaffirmed its 2026 revenue guidance and its path to profitability in 2027, supported by new commercial launches and expense reductions.
The biotech firm is trimming its drug development pipeline and headcount following missed Q3 targets, pivoting toward new commercial launches to reach profit goals.
Read the full storyThe annual loss narrowed, but revenue of $173 million fell short of analysts’ estimates as the company announced workforce and R&D cuts.
Revenue rose from $160 million a year earlier, while the company reaffirmed its expectation of achieving annual GAAP profitability in 2027 despite ongoing losses.